Key result
Switching to SGLT2 inhibitors in patients with chronic heart failure and type-2 diabetes mellitus improved endothelial function compared to other antidiabetic drugs.
Why the study?
SGLT2 inhibitors improved vascular function in non-human experimental models, but their effect on endothelial function in patients with chronic heart failure and type-2 diabetes mellitus required clinical evaluation.
Does switching to SGLT2 inhibitors improve endothelial function in outpatients with chronic heart failure and type-2 diabetes mellitus?
Observational (n=45)
No
Does switching to SGLT2 inhibitors improve endothelial function in outpatients with chronic heart failure and type-2 diabetes mellitus?
Switching to SGLT2 inhibitors in patients with chronic heart failure and type 2 diabetes mellitus is associated with a significant improvement in endothelial function.
Answers are grounded in this paper and cite their sources.
Switching to SGLT2 inhibitors was associated with improved endothelial function in this cohort; extends low-certainty evidence but leaves open need for outcome trials.
PURPOSE: The use of sodium-glucose-cotransporter-type-2 inhibitors (SGLT2i) was associated in previous studies with an improved vascular function in non-human experimental models. We therefore sought to evaluate possible changes in endothelial function assessed by flow-mediated dilation (FMD) in patients with chronic heart failure (CHF) and type-2 diabetes mellitus (T2DM), switching from other oral hypoglycemic agents to SGLT2i in an observational study. METHODS: Twenty-two consecutive outpatients with CHF and T2DM were enrolled after switching to SGLT2i therapy, and compared with 23 consecutive controls from the same registry comparable for principal clinical characteristics. In all patients, endothelial function was assessed by FMD at baseline and after 3 months of follow-up. RESULTS: Three months of therapy with SGLT2i were associated with a statistically significant improvement in endothelial function (19.0 ± 5.7% vs 8.5 ± 4.1%, p < 0.0001); baseline levels of FMD were comparable between groups (p n.s.). Therapy with SGLT2i was significantly associated to improved FMD levels even at multivariable stepwise regression analysis (p < 0.001). CONCLUSIONS: Switch to SGLT2i in patients with CHF and T2DM was associated in an observational non-randomized study with an improved endothelial function.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2021) conducted an observational in Chronic Heart Failure and Type-2 Diabetes Mellitus (n=45). SGLT2 inhibitors vs. Other antidiabetic drugs was evaluated on Endothelial function assessed by flow-mediated dilation (FMD) (p=<0.0001). Switching to SGLT2 inhibitors in patients with chronic heart failure and type-2 diabetes mellitus improved endothelial function compared to other antidiabetic drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: